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Abstract
Background:  The greatest challenges in vaccine development include optimization of DNA
vaccines for use in humans, creation of effective single-dose vaccines, development of delivery
systems that do not involve live viruses, and the identification of effective new adjuvants. Herein,
we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our
technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with
cationic liposomes and administered intranasally.
Results: We developed a novel and non-toxic formulation of cationic liposomes, in which the
DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to
immunize mice by intramuscular or intranasal routes. Although both liposome formulations
induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not
reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65,
carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli
in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma
preservation, results similar to those found in mice vaccinated intramuscularly four times with
naked DNA-hsp65 (total of 400 μg).
Conclusion: Our objective was to overcome the significant obstacles currently facing DNA
vaccine development. Our results in the mouse TB model showed that a single intranasal dose of
COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four
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intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of
DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and
easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines
to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control
of this infectious disease.
Background
Mycobacterium bovis, bacilli Calmette-Guérin (BCG) has
been widely administered to newborns throughout the
world showing to be effective in the prevention of child-
hood tuberculosis (TB) but not in the reactivation of pul-
monary disease or human immunodeficiency virus-
associated TB. Development of a more effective, standard-
ized, affordable vaccine with durable activity and fewer
side effects has been considered a major international
public health priority. The need to develop new vaccines
is supported by some recent information: 1- data on the
natural history and immunology of infection with M.
tuberculosis; 2- reanalysis of the role of nontuberculous
mycobacteria in protection against TB; 3- the understand-
ing of BCG limitations; and 4- the development of molec-
ular techniques that have permitted the identification of
immunodominant antigens and new methods of antigen
delivery. Vaccine types under investigation against TB
include attenuated or enhanced live whole-cell, inacti-
vated whole-cell, subunit, virus-vectored and DNA vac-
cines, followed by several immunization strategies, as
prime-boost protocols. Several of these candidate vaccines
have demonstrated activity in animal models that is equal
or superior to that of BCG, and trials in human subjects
are currently under way [1].We have previously demon-
strated that a DNA vaccine encoding the mycobacterial
65-kDa heat shock protein (DNA-hsp65) protected mice
and guinea pigs from challenge with a virulent strain of M.
tuberculosis [2] and cured previously infected mice when
administered as naked DNA by intramuscular injection
[3]. We have also shown that the therapeutic use of DNA-
hsp65 in combination with antimycobacterial drugs
shortens the duration of the TB treatment, improves the
treatment of latent TB infection, and is effective against
multi-drug resistant TB [4].
In spite of some isolated negative experimental results [5],
DNA vaccines have in general proved to be safe and well
tolerated in preclinical and clinical studies [6]. The naked
plasmid DNA molecules have not caused any adverse
effects on the biochemical and hematological blood val-
ues and have caused neither detectable organ pathology
nor systemic toxicity [7]. In addition, there has been no
evidence of autoimmunity, development of anti-nuclear
or double-stranded DNA antibodies, or plasmid DNA
(pDNA) integration into chromosomes [7-10]. Although
this approach has been shown to be highly effective in
several experimental models, in general a large amount of
pDNA administered several times is required to induce
this protective immune response. The injection of naked
pDNA could lead to its degradation resulting in a reduced
transfection efficiency into APCs [11]. Moreover, in early
studies of DNA vaccines, experimental data showed that
rodents injected with foreign genes expressed antigens,
produced antibodies, showed cell-mediated immune
responses and achieved protective and long-lasting
immunity [12]. However, as these vaccines moved into
primate studies and human safety trials, excitement
waned. In primate trials, naked DNA failed to generate a
successful response [13]. Similar results were observed in
our own studies: When we tested the ability of the naked
DNA-hsp65 preparation to prevent TB infection in cattle,
we did not observe the immunogenicity seen in our
mouse model (unpublished data). We have therefore pur-
sued various strategies that allow the use of lower
amounts of pDNA with the preservation of the immune
protective effects and a simplified vaccination scheme.
Recent approaches to improving the performance of DNA
vaccines involves the use of a wide range of adjuvants and
delivery systems [14]. Our group has been working on an
improvement of DNA-hsp65 vaccination using a drug
delivery system. We have previously shown that the intra-
muscular injection of PLGA [Poly(lactic-co-glycolic acid)]
microspheres containing 30 μg of DNA has controlled TB
in mice and guinea-pigs [2,15]. Another strategy for DNA
delivery is the utilization of cationic liposomes. Since the
description of liposome in 1965 by Bangham et al. [16],
several studies have demonstrated the feasibility of this
structure as a delivery system for drugs, peptides, proteins,
and DNA. Currently, liposomes are recognized as efficient
immunoadjuvants, improving the immune response to
various antigens [17-19]. As drug carriers, liposomes are
biocompatibile, easy to prepare, and have several formu-
lations that have been approved for clinical application
[20]. Gregoriadis and colleagues [21] developed a func-
tional cationic liposome entrapping a DNA vaccine
encoding the S (small) region of the hepatitis B surface
antigen (HBsAg), that induced an effective immune
response. These liposomes had a 16:8 μmol EPC:DOPE
(egg phosphatidylcholine:1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine) ratio and the cationic lipid DOTAP
(1,2-dioleoyl-3-trimethylammonium-propane) in the
range of 4 to 8 μmol, with the mean diameter of 650 nm.BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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Nonetheless, when the DNA was complexed on the sur-
face of liposomes with the above-mentioned composi-
tion, the resulting liposomes were too large (10–20 μm
mean diameter) and could not be used in the in vivo assays
[22,23]. By making changes to these protocols, we
achieved a 10:1 molar charge ratio (cationic lipid:DNA) in
our liposomes, which resulted in a mean diameter around
1  μm. These liposomes were evaluated using different
immunization routes and doses to detect the level of pro-
tection against M. tuberculosis challenge. Our results
showed that the cationic liposomes when complexed with
DNA-hsp65 (COMP-hsp65) had similar effects to naked
DNA regarding protection against TB. Two main advan-
tages of our new formulation are the 16-fold reduction of
the amount of DNA used and the one-time administra-
tion by a non-invasive intranasal route. Remarkably, his-
tological examination of the lungs in animals immunized
with COMP-hsp65 has revealed minimal granulomatous
lesions with evidence of lesion healing and airway remod-
eling after challenge. We believe that this strategy can be
applied to vaccination against TB in a single dose or in
prime-boost protocols, with the potential to positively
impact the control of this infectious disease.
Results
Liposomes are cationic, with different morphologies and 
appropriate mean size for use in in vivo assays
Table 1 presents the physico-chemical properties of cati-
onic liposomes containing entrapped DNA (ENTR-
hsp65) or with DNA complexed on their surface (COMP-
hsp65). The number-weighted mean diameter and size
distribution were obtained by photon correlation spec-
troscopy (PCS) and dynamic light scattering as previously
described [24,25]. An evaluation using number-weighted
mean diameter and distribution demonstrated that empty
(water-containing) liposomes presented a main popula-
tion of 247.47 ± 86.26 nm (93.96%) and a second one
with 862.92 ± 140.78 nm (6.04%). The ENTR-hsp65 gen-
erated two populations of 244.53 ± 64.05 nm (93.21%)
and 985.92 ± 229.12 nm (6.79%). The mean diameter
and size distribution similarities between empty and
ENTR-hsp65 indicate that the amount of DNA does not
modify the size of the particles. A different pattern was
observed with COMP-hsp65. In this case, the mean size
distribution presented two populations with mean diam-
eters 616.73 ± 152.35 nm (93.4%) and 2749.56 ± 774.90
nm (7.53%). The higher size of COMP-hsp65 suggests the
presence of DNA on the surface of liposomes.
The zeta potential of the structures was similar and
showed positive values, indicating that the colloidal struc-
tures were cationic (Table 1). These results indicate that
for a 10:1 molar charge ratio (cationic lipid:DNA), the
association of DNA does not influence the zeta potential.
Both the colloidal structures were stable in terms of mean
diameter and size distribution during storage at 8°C, for 2
months (data not shown).
Transmission electron microscopy using negative-staining
techniques were used to investigate the morphology of the
structures. Figure 1 represents the electronic micrograph
of the three liposome preparations. The results confirm
our previous evaluation of mean diameter and size distri-
bution. The empty liposomes (Figures 1A and 1B) appear
to be spherical with diameter similar to the main popula-
tion 250 nm obtained by PCS. The larger structures
observed in the Figure 1A could be generated by aggrega-
tion due to the dehydration-rehydration process and are
in accordance with the second population identified by
PCS and dynamic light scattering measurements. In com-
parison to ENTR-hsp65 (Figures 1E and 1F), the micro-
graphs of COMP-hsp65 (Figures 1C and 1D) show the
much higher density of DNA associated with the surface
of liposomes. The images also demonstrated that COMP-
hsp65 liposomes are larger structures than ENTR-hsp65
liposomes, confirming the mean diameter and size distri-
bution measurements.
Table 1: Physico-chemical properties of liposomes
Liposome type Mean Diameter  Zeta Potential 
nm ± SD(i) (%)(ii) mV ± SD(iii)
Entrapping DNA-hsp65 244.53 ± 64.05 (93.21)
985.92 ± 229.12 (6.79)
32.8 ± 4.0
Complexing DNA-hsp65 616.73 ± 152.35 (93.4)
2749.56 ± 774.90 (7.53)
27.3 ± 2.3
Empty 247.47 ± 86.26 (93.96)
862.92 ± 140.78 (6.04)
26.9 ± 2.4
(i) Mean ± standard deviation (SD). Liposome composition- EPC:DOTAP:DOPE 50:25:25 molar. Liposomes containing DNA-hsp65 at molar charge 
ratio 1:10 (cationic lipid:DNA). Diameter measurements were done in independent samples: n = 8 for liposomes complexed with DNA-hsp65 and 
n = 9 for liposomes entrapping DNA-hsp65 and empty liposomes.
(ii) Percentages refer to distribution number-weighted of particles.
(iii) Mean ± standard deviation (SD). Zeta potential measurements in three independent samples (n = 3)BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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Liposomes are non-cytotoxic when added to cell cultures
As our main goal was to perform in vivo assays with lipo-
some formulations in mice, we evaluated the in vitro cyto-
toxicity of these structures compared to naked DNA
(Figure 2). Using the MTT assay, J774 cells were trans-
fected with each of the liposome formulations (ENTR-
hsp65 or COMP-hsp65) or with naked hsp65 showing
more than 60% of cell viability even with high concentra-
tions of DNA (200 μg/mL, corresponding to 400 μL of
liposome). Since our formulations exhibited no differ-
ence in toxicity when compared with naked DNA, except
for the highest concentration analyzed for Blank (empty)
liposome and ENTR-hsp65, these carriers were selected to
perform in vivo assays with the dose of 50 μg of pDNA.
Immunization with liposomes carrying DNA-hsp65 induces 
antibody production of Th1 pattern
Since the liposomes were not toxic to cells, we analyzed
the immunogenic potential of our structures beginning
with the evaluation of antibody production after immuni-
zation. Thirty days after injection with four doses of naked
DNA or a single dose of liposomes, we analyzed the pres-
ence of two subtypes of anti-hsp65 antibodies in serum of
BALB/c mice. As shown in Figure 3, naked DNA induced
a mixed pattern of immune response as previously
observed, with IgG1 and IgG2a production. Interestingly,
we observed a polarized pattern of antibody production
after immunization with cationic liposomes carrying
hsp65, with exclusive IgG2a subtype production using
only 50 μg of DNA, suggesting a Th1 immune response
pattern. However, this IgG2a level was lower than the
level induced by naked DNA immunization.
The route and dose of immunization drive the level of 
protection against M. tuberculosis
Although a single intramuscular dose of ENTR-hsp65 or
COMP-hsp65 induces modulation of the immune system,
these formulations do not prevent TB infection in mice
In vitro evaluation of cationic liposomes cytotoxicity on J774  macrophage cell line Figure 2
In vitro evaluation of cationic liposomes cytotoxicity 
on J774 macrophage cell line. Confluent cell populations 
were incubated with: naked hsp65 or vector; liposome 
entrapped (ENTR) hsp65 or vector; liposome complexed 
(COMP) hsp65 or vector. Macrophages were cultured in 
RPMI medium as the control. The vaccine agents or controls 
were added to the culture in concentrations ranging from 
10–200 μg/mL of DNA, the equivalent of 20–400 μL/mL of 
liposome, for 24 hours. After treatment, MTT reagent was 
added to the culture medium and after 4 h of incubation, 
medium was removed and 100 μL of isopropanol containing 
HCl 0.1 mol/L was added to the wells to dissolve formazan 
crystals. Values are the mean ± SD of percent of viable cells 
compared to the control. The data represent one of three 
separate experiments performed in quadruplicate. *p < 0.01 
were considered significant when compared to naked hsp65 
group.
Negative-staining electron micrographs of liposomes (EPC/ DOPE/DOTAP 50:25:25% molar) Figure 1
Negative-staining electron micrographs of lipo-
somes (EPC/DOPE/DOTAP 50:25:25% molar). A and 
B represent empty (water- containing) liposomes; C and D 
represent liposome entrapping DNA at a 10:1 molar charge 
ratio (cationic lipid:DNA); E and F represent liposomes com-
plexing DNA at the same molar charge ratio. Bars indicate: 
A, C, E – 1000 nm; B, D, F – 200 nm.BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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when compared with the classic DNA vaccine (Figure 4).
The next step was to evaluate the protection against M.
tuberculosis using different doses and routes of immuniza-
tion. We attempted to improve the activity of liposomes
by using two intramuscular doses of these preparations.
This strategy showed a slight colony forming units (CFU)
reduction, but overall it was not effective. However, when
we delivered COMP-hsp65 intranasally in a single dose
(25 μg of DNA) a higher protection was observed, with a
significant reduction of 1.97 ± 0.23 log in the bacterial
load between the saline group and COMP-hsp65. This
CFU reduction was the same as we observed when we vac-
cinated intramuscularly with four doses (400 μg of total
DNA) of naked hsp65 and also similar to results with BCG
immunization (Figure 4). Thus intranasal delivery of
COMP-hsp65 afforded effective protection in mice using
a lower DNA dose. Additionally, four doses of naked
hsp65 delivered intranasally did not induce reduction of
bacilli number in the lungs (data not shown).
Protection conferred by COMP-hsp65 was followed by 
histological examination
Histological analysis of lung sections from the saline con-
trol group (Figure 5) showed tissue damage caused by
severe inflammation, with few lymphocyte infiltrations
and high numbers of foamy macrophages. In contrast,
Anti-hsp65 subtype antibody production in mice immunized with liposomes or naked DNA Figure 3
Anti-hsp65 subtype antibody production in mice immunized with liposomes or naked DNA. BALB/c mice were 
immunized by intramuscular injection with 4 doses of 100 μg of naked DNA or a single dose of 100 μL of liposome (corre-
sponding to 50 μg of DNA). Anti-hsp65 antibody levels were evaluated in mice serum by ELISA 30 days after the last immuni-
zation. A) IgG2a and B) IgG1 isotypes. Results are presented by mean ± SD of optical density. *p < 0.05 were considered 
significant when compared to saline group or their respective controls.BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
Page 6 of 13
(page number not for citation purposes)
mice that were immunized with COMP-hsp65 exhibited
smaller pneumonic areas with a cell infiltrate containing
a predominance of lymphocytes and macrophages. More-
over, the morphometric analysis (Figure 6) showed that
70% of the lung was damaged in the saline control group,
while in mice immunized with COMP-hsp65 lung dam-
age was reduced to 30%. These effects of liposome immu-
nization were comparable to those induced by naked
hsp65 and BCG.
The protection of COMP-hsp65 could be related to a Th1 
skewed immune response
Since certain cytokines play an important role in the
immune response to M. tuberculosis, we investigated the
pattern of cytokine production in the lungs of mice from
saline controls and mice immunized according to proto-
cols that had shown protection, e.g., naked DNA and
COMP-hsp65. When mice were challenged with M. tuber-
culosis, we observed a Th1 cytokine pattern with an
increase of IFN-γ, IL-12 and IL-10 production when com-
pared to uninfected animals (Figure 7). However, immu-
nization with naked hsp65 and COMP-hsp65 induced a
significant increase of IFN-γ and a significant decrease in
IL-10 compared to saline control mice. IL-12 expression
was not altered by these immunization protocols. Addi-
tionally, we did not observe differences in IL-4 production
among the groups (data not shown).
Discussion
Our group has focused on the heat shock protein pro-
duced by Mycobacterium leprae (hsp65) as a vaccine anti-
gen against several pathologies including TB,
leishmaniasis [26], diabetes, arthritis [3,4,27-29] and can-
cer. The success of hsp65 vaccination in these different
diseases reflects its effectiveness as an immunodominant
antigen, and also suggests that it possesses hsp-dependent
properties, such as causing the formation of peptide-hsp
complexes [30]. When DNA-hsp65 was used to vaccinate
mice intramuscularly it elicited an effective immune
response only at high DNA doses, which we postulate
Determination of M. tuberculosis growth in lungs from mice immunized with liposomes by different routes Figure 4
Determination of M. tuberculosis growth in lungs from mice immunized with liposomes by different routes. 
BALB/c mice were immunized by: a) a single dose or two doses of liposomes (50 μg of DNA each) by intramuscular injection 
at a 15-day interval, b) a single dose of liposomes (25 μg) by intranasal instillation, c) four doses of naked DNA (100 μg each) 
by intramuscular route at a 15-day interval or d) one dose of BCG (Moreau strain) given by subcutaneous injection of about 
105 live bacteria in 100 μl saline. Thirty days after the last dose, mice were challenged intra-tracheally with M. tuberculosis 
H37RV and 30 days post infection we performed CFU analysis. Data represent the mean log10 CFU counts ± SD of six mice 
per group of one of three independent experiments. *p < 0.01 were considered significant when compared to the saline group.BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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were necessary because of the loss of a considerable
amount of injected pDNA via deoxyribonuclease degrada-
tion. To circumvent this problem, drug carriers such as
microspheres or liposomes have been developed which
protect DNA from extracellular enzymes and could
improve DNA vaccination results.
Here we showed that cationic liposomes could be used as
delivery system for low doses of DNA-hsp65, causing pro-
tection equivalent to that of naked DNA against M. tuber-
culosis. Most important were the findings that the use of
liposomes resulted in a 16-fold reduction in the amount
of DNA used in the immunization and that this could be
administered in a single dose through a non-invasive
route.
The physico-chemical characterization of liposomes con-
taining DNA entrapped or complexed on the surface dem-
onstrated that these structures have positive zeta
potential. This cationic characteristic supports DNA deliv-
ery to the cells since the driving force for the binding of
lipid structures to the negatively charged cell membrane is
electrostatic [31]. Furthermore, different DNA-liposome
association methods produced liposomes with different
characteristics of mean diameter and morphology. Our
findings are in accordance with the studies of Perrie and
colleagues [23], which described the DNA localization in
dehydrated-hydrated vesicles obtained by entrapping or
complexing methods. The entrapping process distributes
the DNA along the bilayers and the complexing concen-
trates the DNA on the external surface of the vesicle. How-
ever the mean size obtained in our study with complexed
DNA on the liposome surface was smaller than previously
reported [23] due to our modified protocol, rigid temper-
ature control (4°C) and intense vortexing.
In vitro studies showed that our liposome preparations are
safe with low cytotoxicity even at high concentrations.
Also, in vivo studies showed that the immunization with
liposomes skewed the antibodies production to IgG2a
without IgG1 production, suggesting a polarization to
Th1 pattern of immune response. This profile is similar to
previous data of our group injecting PLGA microspheres
carrying DNA-hsp65 plus trehalose 6,6'-dimycolate (an
adjuvant derived from cell walls of mycobacteria) by
intramuscular route [15]. Results from immunization
with naked hsp65 showed a mixed antibody response and
Morphometric analysis of lung parenchyma from mice immu- nized with COMP-hsp65 or naked hsp65 Figure 6
Morphometric analysis of lung parenchyma from 
mice immunized with COMP-hsp65 or naked hsp65. 
We performed morphometric analysis of lung histology sec-
tions. Data represent the mean percent of pulmonary area 
committed to inflammation ± SD of six mice per group of 
one of three independent experiments. *p < 0.01 were con-
sidered significant when compared to the saline group. Comparison of lung parenchyma from mice immunized with  COMP-hsp65 or naked hsp65 Figure 5
Comparison of lung parenchyma from mice immu-
nized with COMP-hsp65 or naked hsp65. Lung sections 
of mice immunized with one intranasal dose of COMP-hsp65 
(25 μg) were compared with lung sections from mice that 
received four intramuscular doses of naked DNA (400 μg), 
BCG or saline. Thirty days after the last dose, mice were 
challenged intra-tracheally with M. tuberculosis H37RV and 30 
days post infection we performed histological analysis of the 
lung. (A) non-infected; (B) saline; (C) naked hsp65; (D) 
COMP-hsp65 and (E) BCG groups. Representative sections 
of HE staining. Magnifications: ×65.BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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levels of IgG2a antibodies than seen with the liposome
delivery system. These differences could be related to the
amount of DNA, the different doses or to the immuniza-
tion route. However, the liposomes are the delivery vehi-
cle of choice as they elicited Th1 polarization without the
use of additional adjuvant.
Our analysis of different immunization protocols showed
that one intramuscular dose (which delivers 50 μg of
DNA) did not promote a significant reduction in CFU
number (Figure 4). However, all groups immunized twice
with liposome exhibited a slight reduction in bacterial
growth, suggesting that the constituents of liposomes may
have intrinsic immunostimulatory properties. To analyze
a new route of delivery, we used the immunization
through the nasal mucosa that provides a simple, non-
invasive route to deliver DNA vaccines stimulating
mucosal immunity [32]. While this worked effectively for
our liposome bearing DNA-hsp65, the intranasal delivery
of naked DNA was ineffective. Possibly naked DNA was
destroyed by physical and chemical mucosal barriers that
abrogate the gene transfection including endonucleases,
enzymes present on mucus, low pH and fast elimination
by ciliate epithelium [33,34], a scenario that can be cir-
cumvented by liposomal carriers. Furthermore, cationic
liposomes have been proved to enhance immune
response against pathogens [32,35] including M. tubercu-
losis [36] when administered intranasally. COMP-hsp65
intranasal instillation conferred a significant impairment
in bacilli growth that was comparable to 400 μg of naked
DNA injected by intramuscular route.
Since the lipids and molar ratio of both liposomes were
similar, the reason that only COMP-hsp65 immunization
achieved effective protection could be due to where the
DNA resides. The higher exposure of DNA on the lipo-
some surface in COMP-hsp65 may favor the interaction of
CpG motifs present in plasmid DNA with receptors such
as endogenous toll-like receptor 9 (TLR9) leading to an
activation of antigen-presenting cells [37]. Another fea-
ture to be considered is that the diameter of the liposomes
could influence the macrophage phagocytosis process, as
showed by Volle et al. [38], which established a relation
between the size of synthetic particles and phagocytosis
efficacy, a result confirmed in rat alveolar macrophages
[39]. Related, we observed that mice immunized with
larger particles (COMP-hsp65) caused a significant reduc-
tion of CFU from infected lung tissue, suggesting that
COMP-hsp65 delivery improved the DNA capture by
immune competent cells. However, additional studies are
required to test this hypothesis.
In addition to protecting against bacterial growth, new
vaccines need to be evaluated for their ability to maintain
the integrity of the tissues involved in the pathology. In
Cytokine production from the lung tissue of mice immunized  with naked DNA-hsp65 or carried by liposome Figure 7
Cytokine production from the lung tissue of mice 
immunized with naked DNA-hsp65 or carried by 
liposome. Mice were immunized by intramuscular injection 
with naked hsp65 (400 μg) or by intranasal instillation with 
COMP-hsp65 (one dose of 25 μg). Thirty days after the last 
dose, mice were challenged intra-tracheally with M. tuberculo-
sis H37RV and 30 days post infection, IFN-γ (A), IL-12 (B) 
and IL-10 (C) levels were determined by ELISA in lung 
homogenate. Data represent the mean ± SD of six mice per 
group of one of three independent experiments. *p < 0.01 
were considered significant when compared to the saline 
group.BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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our study, COMP-hsp65 vaccination preserved the pul-
monary parenchyma (Figure 5) and reduced tissue
inflammation (Figure 6). Therefore, liposomes com-
plexed with DNA-hsp65 showed the ability to stimulate
the immune system in a manner that resulted in bacilli
reduction and lung preservation. These effects could be
due to cytokines present in the pulmonary parenchyma,
as high levels of IFN-γ were detected in mice immunized
with both naked hsp65 and COMP-hsp65 (Figure 7). This
finding suggests that COMP-hsp65 is a promising vaccine,
since a Th1 immune response could be important for the
development of protective immunity against M. tuberculo-
sis infection [29,40-42]. On the other hand, production of
the regulatory cytokine IL-10 was reduced in vaccines that
conferred effective protection against M. tuberculosis infec-
tion (naked hsp65 and COMP-hsp65), when compared to
non-immunized mice. This is particularly interesting
because the role of IL-10 in TB is controversial, since it has
been reported that IL-10-/- mice are not protected from
infection [43,44] while others showed that increases of IL-
10 expression leads to a down regulation of the immune
response against TB [45,46]. Indeed, our group recently
showed that the evaluation of many immunological
parameters is necessary to understand the mechanisms
underlying the immune response against TB [47,48]. In
our model, it seems that a combination of the increase of
IFN-γ expression and a decrease of IL-10 expression
improves the immune response leading to bacilli reduc-
tion and lung parenchyma preservation.
The utilization of cationic liposomes as a drug delivery
system represents an advance for vaccine technology,
which has been growing in recent years. Liposomes deliv-
ering amphotericin B is used in the therapy of visceral
leishmaniasis patients with great efficacy [49]. Okada and
colleagues showed 100% of survival in a cynomolgus
monkey model infected with M. tuberculosis, using BCG
plus DNA-hsp65 vaccine carried by liposomes [50]. More-
over, several articles pointed out the effects of DNA-hsp65
immunization in different protocols and a study has been
done to achieve an effective, cost-convenient and safest
vaccination scheme (Souza et al., in press). Additionally,
two DNA vaccines for veterinary use (horse and salmon)
are in the market and there are several reports showing the
safety of DNA vaccines when tested in preclinical and clin-
ical trials [51]. We recently tested DNA-hsp65 vaccine in a
phase I/II clinical trial in cancer patients and the results
showed no toxicity or autoimmunity reactions (Michalu-
art et al., in press). Considering that liposomes are cur-
rently used in medical products and DNA vaccines are
under development, their combination in TB vaccination
offers a promising approach to fighting this disease.
Conclusion
Here we showed effective protection against TB with a sin-
gle immunogen delivered by a safe and efficient carrier
system without any additional adjuvant. We achieved a
16-fold reduction in the plasmid DNA amount adminis-
tered in only one dose with the additional advantage of
using a non-invasive route of administration (intranasal
route). The data presented here show the importance of
the proper association of the delivery method and the
optimization of the route and dose used for immuniza-
tion.
Methods
Plasmid derivation
The naked hsp65 construct was derived from the pVAX1
vector (Invitrogen, Carlsbad, CA, USA). The 3.3 kb frag-
ment of M. leprae hsp65 was subcloned into Bam HI and
Not-I restriction sites (Gibco BRL, Gaithersburg, MD,
USA). pVAX1 uses a CMV from intron A as a promoter.
The parental vector was used as control. Plasmid DNA was
obtained from transformed DH5α E. coli cultured in LB
liquid medium (Gibco BRL, Gaithersburg, MD, USA) con-
taining kanamicin (50 μg/mL). The plasmids were puri-
fied using the Endofree Plasmid Giga kit (Qiagen,
Valencia, CA, USA). Plasmid concentration was deter-
mined by spectrophotometry at the wave lengths 260 and
280 nm using the Gene Quant II apparatus (Pharmacia
Biotech, Buckinghamshire, UK).
Liposomes preparation and characterization
Lipids
Egg phosphatidylcholine (EPC), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE) and 1,2-dioleoyl-3-tri-
methylammonium-propane (DOTAP) were purchased
from Avanti Polar Lipids.
The cationic liposomes were prepared in three steps: (i)
preparation of liposomes according to Bangham's
method [16], (ii) dehydration by lyophilization and (iii)
hydration to obtain dehydrated-hydrated vesicles (DRVs)
described by Kirby and Gregoriadis [52]. Briefly, the
required amounts of all lipid stock solutions in chloro-
form (EPC/DOPE/DOTAP 50/25/25% molar) were
mixed and dried to a thin film using a rotary evaporator in
a 650 mmHg vacuum for 1 hour. The dried lipid film was
hydrated with water at 30°C above its phase transition
temperature. The liposomes were extruded through two
stacked polycarbonate membranes (100 nm nominal
diameter) 15 times at a nitrogen pressure of 12 kgf/cm2.
Cationic liposomes entrapping plasmid DNA
DNA (pVAX-hsp65) in water solution was mixed with the
extruded liposomes, frozen, and freeze-dried overnight.
Controlled rehydration of the dry powders with salineBMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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solution (NaCl 0.9%) resulted in the formation of lipo-
somes entrapping the DNA referred as ENTR-hsp65 [23].
Cationic liposomes complexed with plasmid DNA
The complexed structure containing higher DNA density
on the surface (COMP-hsp65) was obtained through a
modification of the protocol described by Perrie and Gre-
goriadis [23]. Preformed empty dehydrated-hydrated
liposomes (1.44% NaCl) were complexed with water
resuspended DNA reaching a 0.9% NaCl final concentra-
tion. The complexing was carried out at 4°C under vortex
for size control.
The cationic lipid
DNA molar charge ratio of 10:1 was used in both lipo-
somal structures. The biophysical characterization of lipo-
somes was assessed as follows:
Average hydrodynamic diameter and distribution
The average hydrodynamic diameter and size distribution
were determined by Photon Correlation Spectroscopy
(PCS) and dynamic laser light scattering (Malvern Auto-
sizer 4700) using a Ne-He laser and measurements were
taken at a scattering angle of 90°. Particle diameter was
calculated from the translational diffusion coefficient by
using the Stokes-Einstein equation: d(H) = (kT)/(6πηD)
where: d(H) is the hydrodynamic diameter, D is the trans-
lational diffusion coefficient, k is the Boltzmann's con-
stant, T is the absolute temperature, and η is the viscosity.
The mean diameter and distribution of particle sizes were
estimated by CONTIN algorithm analysis. Results were
calculated in triplicate and expressed by the intensity of
scattered light and converted to number-weighted mean
diameter and size distribution automatically by the soft-
ware of the equipment.
Zeta Potential
The zeta potential was measured on a Zetasizer 3000 –
Malvern by diluting empty cationic liposomes or those
containing DNA in appropriate volume of saline solution
(NaCl 0.9%) at pH 6.4, 25°C.
Morphology
Transmission electron microscopy and the negative stain-
ing method were used to visualize the morphology of the
lipid structures. Carbon-coated 200 mesh copper grids
with collodion (parloidin with cellulose acetate) film
were used. Each liposome preparation was diluted to 1
mM total lipid and then applied to the carbon grid. After
incubation for 5 minutes at room temperature, the excess
was blotted. One drop of uranyl acetate (1% w/w in saline
solution) was added to the carbon grid and incubated 1
minute at room temperature before the excess was blotted
and air-dried. A Carl Zeiss CEM 902 microscope,
equipped with a Castaing-Henry-Ottensmeyer energy fil-
ter was used. The images were obtained using a CCD cam-
era (Proscan).
All formulations were tested for endotoxin levels with
QCL-1000 Limulus amebocyte lysate. The levels found
were under 0.01 EU/mL.
In vitro cytotoxicity assay
The standard 3-(4,5-diethylthiazoyl-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) colorimetric cytotoxicity
assay was used [53]. J774-macrophage cells were grown in
RPMI medium at 106 cells/mL and added to 96-well cell
culture plates at 105 cells/well. The cells were incubated
for 24 h at 37°C, with 5% CO2. Serial dilutions of the
liposomes or naked DNA in RPMI medium were added as
described below. Cells were incubated with vaccine prep-
arations for 24 h and then 100 μL MTT reagent (5 mg/mL
in RPMI) was added to each well. MTT was allowed to
incubate with the cells for 4 h. The supernatant were aspi-
rated and 100 μL of isopropanol plus HCl 0.1 mol/L was
added to each well. After plate agitation the absorbance of
the solubilized compounds was read on spectrophotome-
ter set at 570 nm. Cell survival at the end of treatment was
calculated as a percentage of the control cells (macro-
phages incubated only in the medium). All assays were
performed in quadruplicate.
Animals
Female 6-week-old BALB/c mice were obtained from the
animal facility of Faculdade de Ciências Farmacêuticas –
Universidade de São Paulo. All experiments were
approved and conducted in accordance with the guide-
lines of the Animal Care Committee of the University.
Infected animals were kept in biohazard facility of Labo-
ratory Biosafety Level 3 and housed in cages within a lam-
inar flow safety enclosure under standard conditions.
Immunization procedures
Immunization was performed by one of the following
treatments, using six animals per group. For BCG immu-
nization, one dose of Moreau strain was given by subcuta-
neous injection of 105 live bacteria in 100 μl of saline. For
naked DNA vaccination, the plasmid with DNA-insert
(DNA-hsp65) was administered by intramuscular injec-
tion of 50 μg in 50 μL of saline solution into each quadri-
ceps muscle in four occasions at two-week intervals (total
dose of 400 μg of plasmid DNA). For liposomes vaccina-
tion, mice received one or two doses of 50 μg of DNA
(equivalent of 100 μL of liposome) by intramuscular
injection. For intranasal delivery of liposomes, animals
were lightly anesthetized with tribromoethanol 2,5%
(Across Organics) and 50 μL of liposome (25 μg of DNA)/
mouse was administered dropwise to external nostrils of
the mice (25 μL per nostril) with a fine pipette tip. Addi-BMC Immunology 2008, 9:38 http://www.biomedcentral.com/1471-2172/9/38
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tionally control animals received parental vector plasmid
pVAX1 entrapped (ENTR) or complexed (COMP) in lipo-
somes, or empty liposomes (blank).
Antibody evaluation
Serum from vaccinated or control mice were collected 30
days after the last dose of each immunization scheme. To
assess antigen-specific antibody levels, 96-well plates
(Maxisorp Nunc-Immuno plates) were treated with 0.1
mL of purified protein (5 μg/mL) in coating solution
(Na2CO3  14.3 mM, NaHCO3  10.3 mM, NaN3  0.02%,
pH9.6), incubated at 4°C overnight, and then blocked
with 1% BSA in PBS for 60 min at 37°C. Serum samples
were applied in serial ten-fold dilutions from 1:10. After
incubating the plates for 2 h at 37°C, anti-mouse biotin-
conjugated IgG1 or IgG2a (A85-1 and R19-15 respec-
tively, from Pharmingen, San Diego, CA, USA) were
added for the detection of specific antibodies. After wash-
ing, plates were incubated at room temperature for 30
min with StreptAB kit (Dako, Carpinteria, CA, USA). The
detection of bound antibodies was conducted by OPD
substrate (Sigma, St Louis, USA) and the reaction was
stopped by the addition of 50 μL of a 16% solution of sul-
furic acid. Optical density was measured at 490 nm.
Experimental infection with M. tuberculosis
The H37Rv strain of M. tuberculosis (American Type Cul-
ture Collection, Rockville, MD) was grown in 7H9 Mid-
dlebrook broth (Difco Laboratories, Detroit, MI) for seven
days. The culture was harvested through centrifugation
and the cell pellet was resuspended in sterile phosphate
buffered saline (PBS) and vigorously agitated. The homo-
geneous suspension was filtered through 2-μm filters
(Millipore, Bedford, MA). Viability of the M. tuberculosis
suspension was pretested with fluorescein diacetate
(Sigma, Saint Louis, MO) and ethidium bromide. Thirty
days after the last immunization the mice were challenged
with  M. tuberculosis. An anterior midline incision was
made to expose the trachea. A 30-gauge needle attached to
a tuberculin syringe was inserted into the trachea and
intratracheal dispersion was used to introduce 105 viable
CFU of M. tuberculosis H37Rv in 100 μl of PBS into the
lungs [27]. Thirty days after the M. tuberculosis challenge
the mice from all groups were euthanized. Control mice
received only intratracheal PBS.
Determination of M. tuberculosis CFU in lungs
The rescue of M. tuberculosis was performed as described
previously [3]. Briefly, the number of live bacteria was
determined by extracting the lower and medium right
lobes of the lung, washed with sterile PBS, followed by
plating 10-fold serial dilutions of homogenized tissue on
Middlebrook 7H11 agar media (Difco) [supplemented
with 0.2% (v/v) glycerol and 10% (v/v) bovine fetal
serum], counting colonies after 28 days at 37°C. The col-
ony-forming units (CFU) are expressed as log10 of CFU/g
lung.
Histology and morphometric analysis of lung parenchyma
At 30 days post-M. tuberculosis infection, the upper right
lobe of each mouse lung was removed and fixed in 10%
formalin. Paraffin blocks were prepared and then sec-
tioned for light microscopy. Sections (5 μm each) were
stained with hematoxylin & eosin (HE). Slides were eval-
uated using a Leitz Model Aristoplan microscope (Ger-
many) connected to a Leica Model DFC280 color camera
(Heerbrugg, Germany) linked to a PC computer. To per-
form morphometric analysis of lung parenchyma, an inte-
grating eyepiece with a coherent system made of a 100-
point grid consisting of 50 lines of known length was cou-
pled to the slides and evaluated through light microscopy.
Volume fraction of collapsed and normal pulmonary
areas was determined by point-counting technique, made
at a magnification of ×400 across 10 random non-coinci-
dent microscopic fields. Points falling on tissue area were
counted and divided by the total number of points in each
microscopic field. Thus data were reported as the frac-
tional area of pulmonary tissue [54].
Cytokine evaluation
For cytokine measurements, the entire left lobe of lung
was removed on day 30 post-M. tuberculosis infection. Tis-
sue was homogenized in 2 ml of RPMI 1640, centrifuged
at 450 × g and the supernatant was stored at -70°C until
assayed. Commercially available enzyme-linked immu-
nosorbent assays with capture and biotinylated mono-
clonal antibodies were used to measure IFN-γ (R4-6A2,
XMG1.2), IL-4 (11B11, BVD6-24G2), IL-10 (JES5-2A5,
SXC-1) and IL-12 (9A5, C17.8) (Pharmingen, San Diego,
CA). The cytokine levels were measured according to the
manufacturer's instructions with sensitivities >10 pg/ml.
Statistical analysis
The data were represented as mean ± SD (n = 6) and ana-
lyzed using GraphPad Prism version 4.03 for Windows
(GraphPad Software, San Diego, CA). The data were com-
pared using Mann-Whitney non-parametric test.
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